Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.”
Email: jackfriday2011(at)hotmail.co.uk
brilliant title (better than mine). Seriously, with a POI patent that should expire in 2011 and a best case estimate for launch in 2009, why bother? Is an approval for marquee value really worth this to Adlor or do Adolor/GSK honestly think they can generate enough sales for such limited potential benefit in POI (or really bolster sales with off-label use) to make some money?
1 comment:
brilliant title (better than mine). Seriously, with a POI patent that should expire in 2011 and a best case estimate for launch in 2009, why bother? Is an approval for marquee value really worth this to Adlor or do Adolor/GSK honestly think they can generate enough sales for such limited potential benefit in POI (or really bolster sales with off-label use) to make some money?
Post a Comment